Retatrutide (LY3437943) is a novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Developed by Eli Lilly, it represents the first compound to engage all three pathways in a single molecule, distinguishing it from dual agonists like Tirzepatide.
Phase 2 Trial Outcomes: The Foundation
The Phase 2 trial (NCT04881706), published in The New England Journal of Medicine in June 2023, enrolled 338 adults with obesity. At 48 weeks, participants in the highest-dose cohort achieved a mean body-weight reduction of 24.2%, with some individuals exceeding 30% total body-weight reduction [1].
This level of weight reduction surpassed published results for both Semaglutide (approximately 15% in the STEP trials) and Tirzepatide (approximately 22.5% in the SURMOUNT-1 trial), establishing Retatrutide as the most potent body-weight reduction peptide in clinical development.
The Glucagon Component: A Differentiating Factor
What separates Retatrutide from existing GLP-1 agonists is its activation of the glucagon receptor. Glucagon stimulates hepatic lipid oxidation and increases energy expenditure, a mechanism absent from GLP-1-only or GIP/GLP-1 dual agonists. Preclinical models have demonstrated that glucagon receptor activation can increase resting metabolic rate by 5 to 10%, partially offsetting the metabolic adaptation that typically accompanies caloric restriction [2].
Researchers have hypothesised that the glucagon component may also confer hepatoprotective effects. Data from the Phase 2 trial showed significant reductions in liver fat content, with MRI-PDFF measurements demonstrating a mean relative reduction of approximately 42% in the highest-dose cohort [1].
Phase 3 Trial Design and Endpoints
The TRIUMPH programme encompasses multiple Phase 3 studies evaluating Retatrutide across different populations:
- TRIUMPH-1: Adults with obesity (BMI 30+) or overweight (BMI 27+) with weight-related comorbidities
- TRIUMPH-2: Adults with type 2 diabetes and obesity
- TRIUMPH-3: Metabolic dysfunction-associated steatohepatitis (MASH)
- TRIUMPH-4: Obstructive sleep apnoea
Primary endpoints include percentage change in body weight from baseline at 72 weeks, with secondary endpoints covering glycaemic parameters, liver fat content, and cardiovascular risk markers.
Preliminary Phase 3 Findings
Early data from the TRIUMPH programme, presented at medical conferences through late 2025, have confirmed and extended the Phase 2 findings. Key observations include:
- Mean body-weight reduction at the highest dose cohort exceeding 25% at 72 weeks
- Clinically significant improvements in HbA1c in the diabetes sub-population
- Sustained reductions in liver fat content, supporting the MASH indication
- Adverse event profiles consistent with the GLP-1 class: nausea, diarrhoea, and vomiting were the most common, predominantly mild to moderate and diminishing over time
Implications for Research Peptide Procurement
The clinical success of Retatrutide has driven substantial demand for the research-grade compound. Laboratories conducting in vitro receptor binding studies, pharmacokinetic modelling, and comparative analyses against Semaglutide and Tirzepatide require verified, high-purity material. The minimum acceptable purity for meaningful receptor binding assays is typically 95%, though most rigorous studies require 99% or above [3].
When sourcing Retatrutide for research, critical quality parameters include:
- HPLC purity verification (not less than 99%)
- Mass spectrometry confirmation of molecular identity
- Endotoxin testing (below 0.5 EU/mg for cell culture applications)
- Documented supplier verification through independent rating systems such as Finnrick
Regulatory Timeline
Eli Lilly has indicated plans to submit regulatory applications based on Phase 3 data, with potential approvals anticipated in late 2026 or early 2027. Researchers studying the compound now are positioning their work ahead of the expected surge in clinical and academic interest following regulatory decisions.
References
- [1] Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- [2] Kosinski JR, et al. "Pharmacology of the glucagon receptor and its implications for metabolic disease." Diabetes Obes Metab. 2012;14(12):1079-1087.
- [3] Verboven K, et al. "Quality requirements for peptide-based receptor binding assays." Anal Bioanal Chem. 2021;413:2871-2883.